Furazolidone

Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity, inhibits AML1-ETO transformed cells with IC50 value of 12.7 μM. Target: Antibacterial Furazolidone is a novel therapeutic strategy in AML patients. Furazolidone can Inhibit the bone-marrow transformation mediated by a series of leukemia fusion proteins. Furazolidone significantly inhibits proliferation of AML cell lines. Furazolidone induces apoptosis of the AML leukemic cells treatment with Furazolidone induces differentiation of AML cell lines.

References:
[1]. Jiang X, et al. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One. 2013 Aug 9;8(8):e72335.

Hazardous ecotoxicological impact of two commonly used nitrofuran-derived antibacterial drugs: Furazolidone and nitrofurantoin.[Pubmed:30711727]

Chemosphere. 2019 May;222:381-390.

This paper discusses the impact of two nitrofuran-derived drugs, namely Furazolidone and nitrofurantoin on growth of oat and common radish as well as their impact on bacteria Allivibrio fischeri and crustaceans Heterocypris incongruens. Results indicated that both compounds were highly phytotoxic for radish (R. sativus) being simultaneously nearly not harmful for oat (A. sativa). Growing inhibition of shoots, roots, fresh matter and photosynthetic pigments is correlated with growing concentration of drugs in soil. Ecotoxicological impact of both compounds on model luminescence bacteria Aliivibrio fischeri and freshwater crustaceans Heterocypris incongruens as a representative organisms of two different level of food chain, is also reported herein, and the obtained data show significant toxicity against these two organisms. Basing on obtained results, it was concluded that both nitrofuran drugs in case of distribution through environment, by improper utilisation after use or unplanned environmental intoxication with unused drugs may cause serious environmental problems and therefore both should be handled with a reasonable care at any step of their production or utilisation.

Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.[Pubmed:30386109]

World J Gastroenterol. 2018 Oct 28;24(40):4596-4605.

AIM: To evaluate the outcomes of Furazolidone- and amoxicillin-based quadruple therapy for treatment of Helicobacter pylori (H. pylori) infection and identify predictors of failed eradication. METHODS: Patients with H. pylori infection treated with Furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the (13)C-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior H. pylori treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. H. pylori eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed H. pylori eradication. RESULTS: Of the 992 patients treated and retested for H. pylori infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. H. pylori eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous H. pylori treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed H. pylori eradication. CONCLUSION: Furazolidone- and amoxicillin-based quadruple therapy for H. pylori infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize H. pylori eradication.

Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity, inhibits AML1-ETO transformed cells with IC50 value of 12.7 μM.

Furazolidone,67-45-8,Natural Products, buy Furazolidone , Furazolidone supplier , purchase Furazolidone , Furazolidone cost , Furazolidone manufacturer , order Furazolidone , high purity Furazolidone